ClinicalTrials HQ

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Active, not recruiting · NCT04515238 · Registry updated 2026-08-20
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLHemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasmActive, not recruitingPhase 22026-08-20NCT04515238

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
German CLL Study Group7

11 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Evangelische Krankenhaus HammHammGermany2
Hamatologische/Onkologische GemeinschaftspraxisAugsburgGermany1
Hämatologisch Onkologische SchwerpunktpraxisWürzburgGermany2
KH Kliniken Maria HilfMönchengladbachGermany2
Klinikum Rechts der Isar - Technische Universitaet MuenchenMunichGermany2
Onkologische SchwerpunktpraxisEsslingen am NeckarGermany3
Stauferklinikum Schwaebisch-GmuendMutlangenGermany1
Universitaetskliniken des SaarlandesHomburgGermany2
Universitaetsklinikum Schleswig-Holstein Campus KielKielGermany6
Universitätsklinik KölnCologneGermany2
Universitätsklinik UlmUlmGermany3